crypto dollar coin Top Featured

Bank of America: restore coverage to AbbVie, give it a "neutral" rating, and target price is $191.Changhong Meiling: It plans to use its own idle funds not exceeding 6.35 billion yuan to invest in wealth management products. Changhong Meiling announced that in order to improve the efficiency of the company's use of funds, increase the company's cash assets income, and maximize the interests of shareholders, the company and its subsidiaries (excluding Zhongke Meiling Cryogenic Technology Co., Ltd. and its subsidiaries) will use their own idle funds not exceeding 6.35 billion yuan (this amount can be used in a rolling way) to invest and purchase products with high safety, good liquidity and a term of less than one year.Modern Pharmaceuticals: Sinopharm Zhijun, the holding subsidiary, obtained the drug registration certificate of Cefotaxime Tablets. Modern Pharmaceuticals announced that Sinopharm Zhijun Pharmaceutical Co., Ltd., the holding subsidiary, recently received the Drug Registration Certificate of Cefotaxime Tablets approved and issued by National Medical Products Administration. Cefopoxime axetil tablets are the third generation cephalosporins taken orally, which are used to treat upper respiratory tract infections and lower respiratory tract infections caused by sensitive bacteria. In 2023, the global sales of preparations will be USD 370 million, and the sales of public hospitals nationwide will be RMB 102 million. The accumulative R&D investment of Sinopharm Zhijun is about RMB 28.45 million. Obtaining the registration certificate will enrich the company's product line, increase market competitiveness and have a positive impact on the company's future development. However, drug sales are easily affected by factors such as policies and market environment, and there are uncertainties.

The wide currency and weak credit logic may continue, and the upward direction of the market volatility will not change. The Shanghai and Shenzhen 300ETF South (159925) is gaining momentum. On December 11, the Shanghai and Shenzhen 300ETF South (159925) closed down by 0.25%, with a turnover of 75,892,100 yuan. The constituent stocks are mixed. In terms of rising, Midea Group led the rise, and Changjiang Power followed suit. In terms of decline, China Ping An led the decline, while Contemporary Amperex Technology Co., Limited followed. In the news, Contemporary Amperex Technology Co., Limited, the power battery giant, once again announced that it will build a power battery factory overseas, which will also become the company's third battery factory in Europe. Bank of China Securities said that the important meeting at the end of the year is about to land, and the market may face fluctuations caused by the expected landing of policies in the short term, but the tone of monetary policy will not change. The logic of "wide money+weak credit" will continue in the short term. Under the expectation of loose monetary policy, the upward direction of market volatility will not change. According to industry insiders, looking forward to 2025, the allocation of A-share industry can be developed around three main lines: first, the direction of domestic macro-circulation, attaching importance to "duality and innovation", "debt conversion" and new growth points in the consumption field; Second, science and technology are self-reliant: pay attention to artificial intelligence industry, self-controllable, new energy technology, aerospace information technology and data elements; The third is to open wider to the outside world: pay attention to cross-border e-commerce, digital trade, tax exemption and inbound tourism. You can use the Shanghai and Shenzhen 300ETF South (159925) to lay out the core assets with one click.The price of basic load electricity delivered in France the next day rose by 12.8% to 190 euros/megawatt hour.Zhewen Internet: Zhejiang Internet (600986) announced on the evening of December 11th that the company intends to authorize the management of the company to make an independent decision to dispose of the stock of Doushen Education Technology (Beijing) Co., Ltd. (hereinafter referred to as "Doushen Education") held by the company through centralized bidding or block trading. The authorization period is within 36 months from the date of deliberation and approval by the shareholders' meeting. As of the date of announcement, the company holds 61.06 million shares of Doushen Education, accounting for 2.95% of the total share capital of Doushen Education, and will lift the restriction on sales on December 29, 2024.

SDIC Power and others have invested in the establishment of a new energy development company. The enterprise search APP shows that recently, Ganzi Yalongjiang Energy Development Co., Ltd. was established with Zhang Peng as its legal representative and a registered capital of 500 million yuan. Its business scope includes: solar power generation technical services; Research and development of emerging energy technologies; Technical services for wind power generation; Energy storage technology services, etc. Enterprise equity penetration shows that the company is jointly owned by Yalong River Basin Hydropower Development Co., Ltd. and Ganzi Energy Development Group Co., Ltd., a subsidiary of SDIC Power.Modern Pharmaceuticals: Sinopharm Zhijun, the holding subsidiary, obtained the drug registration certificate of Cefotaxime Tablets. Modern Pharmaceuticals announced that Sinopharm Zhijun Pharmaceutical Co., Ltd., the holding subsidiary, recently received the Drug Registration Certificate of Cefotaxime Tablets approved and issued by National Medical Products Administration. Cefopoxime axetil tablets are the third generation cephalosporins taken orally, which are used to treat upper respiratory tract infections and lower respiratory tract infections caused by sensitive bacteria. In 2023, the global sales of preparations will be USD 370 million, and the sales of public hospitals nationwide will be RMB 102 million. The accumulative R&D investment of Sinopharm Zhijun is about RMB 28.45 million. Obtaining the registration certificate will enrich the company's product line, increase market competitiveness and have a positive impact on the company's future development. However, drug sales are easily affected by factors such as policies and market environment, and there are uncertainties.On the 11th, iron ore fell by 1.64%, and the latest main contract positions changed as follows. According to the exchange data, as of December 11th, the main contract iron ore was closed at 2501, up or down by -1.64%, with a turnover of 165,400 lots. The position data showed that the top 20 seats were clear, and the difference position was 14,975 lots. Iron ore futures contracts totaled 429,100 lots, a decrease of 195,200 lots from the previous day. The first 20 seats in the contract held 462,200 lots, a decrease of 6,055 lots from the previous day. There were 481,400 short positions in the top 20 seats of the contract, an increase of 7,172 lots over the previous day. (Sina Futures)